You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
At AGBT, UCSC's Karen Miga provided updates on the human pangenome reference project and the telomere-to-telomere consortium's genome assembly work.
AMP AD 2.0 will look to bring precision medicine technologies to Alzheimer's biomarker and target discovery over the next five year.
The British genome analysis company will use the proceeds to continue its growth in the field of genomics-driven preventive care.
The two California startups will aggregate genomic and phenotypic data, including social determinants of health, to support and manage decentralized clinical trials.
With a new CEO, the Swiss startup expects to have its consumer-facing mobile app ready by midyear.
The firm posted total software-related revenues of $18.6 million, up 1 percent from $18.4 million in Q4 2019.
With nearly $100 million in new investments since last year, the San Francisco-based informatics firm looks to ramp up its precision oncology partnerships.
The companies will use their respective technologies and expertise to identify multi-gene biomarkers that can be used in cancer drug discovery.
RenalytixAI will provide financial support to the University of Utah in the form of sponsored research into kidney disease progression, treatment, and biomarkers.
Genomenon will integrate its AI-driven Mastermind search engine into the BC|Genome and BC|Insight platforms.
Using technology rooted in pharmacogenomics testing for medical cannabis, the firm claims it can predict immune response to SARS-CoV-2 and test biomarkers for pharma.
Initial partners in the program include Thermo Fisher Scientific, GNS Healthcare, DNAnexus, Personal Genome Diagnostics, and the Wellcome Sanger Institute.
The Israeli bioinformatics firm is also mulling an expansion into human genetics.
Called Intervene, the project will use genomic and health data from biorepositories along with machine learning methods to develop new clinical predictive tools.
Spun out of the Glasgow Precision Oncology Laboratory, Gabriel wants targeted sequencing to become the norm for all somatic cancer patients.
The Chinese firms have agreed to work together to develop commercial analytical and artificial intelligence-based computing platforms for single-cell genomics.
The partners hope that the relationship will expand the reach of the COSMIC database for somatic tumor mutations while also fine-tuning future technology development.
The British companies will collaborate on a database to support ulcerative colitis research and identify new drug targets for the disease.
University of Glasgow spinout Gabriel Precision Oncology will contribute a bioinformatics pipeline derived from cancer tissue samples to accelerate MDx adoption.
The San Francisco-based precision oncology informatics company now has landed $166 million in equity investment since its inception in 2014.
NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.
According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.
Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.
In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.